

SHIONOGI FILES A NEW DRUG APPLICATION FOR OSPEMIFENE ORAL TABLETS 60MG FOR THE TREATMENT OF VULVAR AND VAGINAL ATROPHY

FLORHAM PARK, NJ (April 26, 2012) –Shionogi Inc. (Shionogi) has filed a New Drug Application for Ospemifene oral tablets 60 mg for the treatment of vulvar and vaginal atrophy (VVA) due to menopause, including moderate to severe symptoms of dyspareunia and/or vaginal dryness and physiological changes (parabasal cells, superficial cells and pH) in post-menopausal women.

About Shionogi & Co., Ltd.

Headquartered in Osaka, Japan, Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to placing the highest value on patients. Shionogi's Research and Development currently targets three therapeutic areas: Infectious Diseases, Pain, and Metabolic Syndrome. The Company has provided such innovative medicines as Crestor and Doripenem, which have been successfully delivered to millions of patients. In addition, Shionogi is engaged in new research areas such as allergy and cancer. Contributing to the health of patients around the world through development in these therapeutic areas is Shionogi's primary goal. For more details, please visit www.shionogi.co.jp. For more information on Shionogi Inc., headquartered in Florham Park, NJ, please visit www.shionogi.com.